𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination trial of subcutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology, non-Hodgkin's lymphoma

✍ Scribed by Howard Ozer; James R. Anderson; Bruce A. Peterson; Daniel R. Budman; Edward S. Henderson; Clara D. Bloomfield; Arlan Gottlieb


Publisher
Springer US
Year
1987
Tongue
English
Weight
482 KB
Volume
5
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

✦ Synopsis


Patients with follicular non-Hodgkin's lymphoma (NHL) respond well to chemotherapy but frequently relapse and progress with conversion to more aggressive histology lymphomas. In a prior Cancer and Leukemia Group B (CALGB) trial, oral cyclophosphamide, given as a single agent, was found to be equivalent to a five-drug regimen in remission induction in patients with follicular NHL who had not received prior chemotherapy. Recently, interferon alfa-2b (Intron A; Schering Plough) has been demonstrated to elicit complete or partial responses in up to 50% of patients with nodular NHL who had received prior chemotherapy. In the current CALGB pilot trial, oral cyclophosphamide (100 mg/m2 daily) combined with interferon alfa-2b (2 X 10(6) IU/m2 s.c. on alternate days) is being evaluated, both in previously treated and untreated patients with stage III or IV follicular NHL, for toxicity, safety and efficacy in remission induction. A total of 68 patients have been entered into this study. Four patients are ineligible on pathology review, and 60 have on-study data currently available. Forty-one (60%) had not received prior chemotherapy and 19 (32%) had previously received some form of chemotherapy. Leukopenia was found to be the single, most common toxicity experienced by all patients. Previously untreated patients experienced leukopenia of less than 2,000 WBC/microliter at a significantly higher rate (53% versus 14%) than a similar patient population receiving oral cyclophosphamide as a single agent in the prior CALGB trial. Leukopenia was found to be promptly reversible, however, by dose suspension or adjustment, and other toxicities were demonstrated to be mild and tolerable.(ABSTRACT TRUNCATED AT 250 WORDS)


πŸ“œ SIMILAR VOLUMES


Combination trial of subcutaneous recomb
✍ Ozer, Howard ;Anderson, James R. ;Peterson, Bruce A. ;Budman, Daniel R. ;Cooper, πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 750 KB

## Abstract The follicular non‐Hodgkin's lymphomas (NHL) have been among those tumors demonstrated to show frequent responses to alpha interferon in phase I and II clinical trials. In addition, there are data suggesting that alpha interferon demonstrates synergistic antitumor activity with alkylati

Interferon alfa-2b and chlorambucil in t
✍ Teodoro Chisesi; Giovanni Capnist; Michele Vespignani; Gianluigi Cetto πŸ“‚ Article πŸ“… 1987 πŸ› Springer US 🌐 English βš– 348 KB

Twenty-two patients with non-Hodgkin's lymphoma (NHL) were treated with a combined regimen of interferon alfa-2b (Intron A; Schering-Plough) and chlorambucil to evaluate the response and efficacy in pre-treated or relapsed patients. Ten patients were classified as having follicular lymphoma and 12 d